GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Debt-to-Equity

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Debt-to-Equity : 0.00 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Debt-to-Equity?

Shenzhenlubris Pharmaceuticals Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥23 Mil. Shenzhenlubris Pharmaceuticals Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥8 Mil. Shenzhenlubris Pharmaceuticals Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥8,226 Mil. Shenzhenlubris Pharmaceuticals Co's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Shenzhenlubris Pharmaceuticals Co's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of Shenzhenlubris Pharmaceuticals Co was 0.10. The lowest was 0.00. And the median was 0.02.

SZSE:002294's Debt-to-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.22
* Ranked among companies with meaningful Debt-to-Equity only.

Shenzhenlubris Pharmaceuticals Co Debt-to-Equity Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Debt-to-Equity Chart

Shenzhenlubris Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.08 0.01 0.03 0.01

Shenzhenlubris Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.03 0.03 0.01 -

Competitive Comparison of Shenzhenlubris Pharmaceuticals Co's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Shenzhenlubris Pharmaceuticals Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shenzhenlubris Pharmaceuticals Co's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shenzhenlubris Pharmaceuticals Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Shenzhenlubris Pharmaceuticals Co's Debt-to-Equity falls into.



Shenzhenlubris Pharmaceuticals Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Shenzhenlubris Pharmaceuticals Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Shenzhenlubris Pharmaceuticals Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shenzhenlubris Pharmaceuticals Co  (SZSE:002294) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Shenzhenlubris Pharmaceuticals Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Traded in Other Exchanges
N/A
Address
1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.
Executives
Yan Jie Directors, executives
Yang Jian Feng Secretary, Director
Zhao Song Ping Executives
Liu Jun Executives
Li Ai Zhen Supervisors
Chen Ping Executives
Ye Cheng Hai Director
Lu Feng Executives, directors
Chen Qiong Xing Supervisors
Li Ying Hui Supervisors
Pan Ling Man Independent director
Zhang Zhong Xing Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines